Serdemetan

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameSerdemetan
Drug Alias Name舍迪美丹serdemetanum色德美坦JNJ-1JNJ-26854165
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Actionp53-binding protein Mdm-2 inhibitors
Targetsp53-binding protein Mdm-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJohnson & Johnson Pharmaceutical Research & Development LLC
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A